Germline BRCA2 Mutations Linked to Resistance in Breast Cancer Treatment
Recent research has identified that germline BRCA2 mutations contribute to resistance against CDK4/6 inhibitors in breast cancer treatment. These inhibitors have been pivotal in managing hormone receptor-positive, HER2-negative breast cancer, but their effectiveness is limited by resistance mechanisms. The study highlights that BRCA2 mutations lead to RB1 loss-of-function alterations, which are acquired through persistent homologous recombination defects. This resistance is particularly significant in patients with HR+HER2- breast cancer, a prevalent subtype that accounts for a substantial number of breast cancer-related deaths. The findings suggest that while CDK4/6 inhibitors improve outcomes, their benefits are constrained by genetic alterations that prevent stable proliferative arrest. 
